JP2014513952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513952A5 JP2014513952A5 JP2014506579A JP2014506579A JP2014513952A5 JP 2014513952 A5 JP2014513952 A5 JP 2014513952A5 JP 2014506579 A JP2014506579 A JP 2014506579A JP 2014506579 A JP2014506579 A JP 2014506579A JP 2014513952 A5 JP2014513952 A5 JP 2014513952A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acids
- kda
- seq
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 9
- 238000012986 modification Methods 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 102000045921 human GAA Human genes 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 229920002527 Glycogen Polymers 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 229940096919 glycogen Drugs 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000007345 glycogen storage disease Diseases 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000002132 lysosomal effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478336P | 2011-04-22 | 2011-04-22 | |
| US61/478,336 | 2011-04-22 | ||
| PCT/US2012/034479 WO2012145644A1 (en) | 2011-04-22 | 2012-04-20 | Modified acid alpha glucosidase with accelerated processing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016185075A Division JP2017035091A (ja) | 2011-04-22 | 2016-09-23 | 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014513952A JP2014513952A (ja) | 2014-06-19 |
| JP2014513952A5 true JP2014513952A5 (enExample) | 2015-05-28 |
Family
ID=46000406
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506579A Pending JP2014513952A (ja) | 2011-04-22 | 2012-04-20 | 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ |
| JP2016185075A Pending JP2017035091A (ja) | 2011-04-22 | 2016-09-23 | 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016185075A Pending JP2017035091A (ja) | 2011-04-22 | 2016-09-23 | 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20140186326A1 (enExample) |
| EP (1) | EP2699676A1 (enExample) |
| JP (2) | JP2014513952A (enExample) |
| KR (1) | KR20140037082A (enExample) |
| CN (1) | CN103797115A (enExample) |
| AU (1) | AU2012245280A1 (enExample) |
| BR (1) | BR112013026976A2 (enExample) |
| CA (1) | CA2833371A1 (enExample) |
| CL (1) | CL2013003010A1 (enExample) |
| CO (1) | CO6811810A2 (enExample) |
| CR (1) | CR20130555A (enExample) |
| EC (1) | ECSP13013036A (enExample) |
| GT (1) | GT201300252A (enExample) |
| IL (1) | IL228871A0 (enExample) |
| MA (1) | MA35125B1 (enExample) |
| MX (1) | MX2013012345A (enExample) |
| NI (1) | NI201300110A (enExample) |
| PE (1) | PE20140617A1 (enExample) |
| PH (1) | PH12013502149A1 (enExample) |
| RU (1) | RU2013151875A (enExample) |
| SG (2) | SG194486A1 (enExample) |
| TN (1) | TN2013000427A1 (enExample) |
| WO (1) | WO2012145644A1 (enExample) |
| ZA (1) | ZA201307696B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014130723A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of pompe disease |
| CN114540327B (zh) | 2014-09-30 | 2026-03-24 | 阿米库斯治疗学公司 | 具有增强的碳水化合物的高强度酸性α-葡糖苷酶 |
| MX2018005258A (es) | 2015-11-06 | 2019-09-04 | Biomarin Pharm Inc | Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas. |
| KR102747683B1 (ko) * | 2015-12-30 | 2024-12-31 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| SG11201808455VA (en) | 2016-03-30 | 2018-10-30 | Amicus Therapeutics Inc | Formulations comprising recombinant acid alpha-glucosidase |
| JP7046003B2 (ja) | 2016-03-30 | 2022-04-01 | アミカス セラピューティックス インコーポレイテッド | 高ｍ６ｐ組換えタンパク質の選択方法 |
| EP3293203A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293260A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293259A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| PE20191203A1 (es) | 2016-09-12 | 2019-09-10 | Genethon | Variantes de alfa-glucosidasa acida y usos de las mismas |
| ES2950808T3 (es) | 2017-05-15 | 2023-10-13 | Amicus Therapeutics Inc | Alfa-glucosidasa ácida humana recombinante |
| ES3065816T3 (en) | 2017-06-07 | 2026-05-08 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| KR101942093B1 (ko) * | 2018-01-05 | 2019-01-24 | 인하대학교 산학협력단 | 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물 |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| JP7771045B2 (ja) | 2019-07-09 | 2025-11-17 | ジェネトン | 糖原病（ｇｓｄ）の処置 |
| PH12022551229A1 (en) * | 2019-11-19 | 2023-07-31 | Asklepios Biopharmaceutical Inc | Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5952516A (en) | 1997-05-08 | 1999-09-14 | Genzyme Corporation | Cationic amphiphiles containing multiplesteroid lipophilic groups |
| US6066626A (en) | 1997-10-29 | 2000-05-23 | Genzyme Corporation | Compositions and method for treating lysosomal storage disease |
| US6287857B1 (en) | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
| GB9807464D0 (en) * | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
| CA2353522A1 (en) | 1998-12-07 | 2000-06-15 | Pharming Intellectual Property B.V. | Treatment of pompe's disease |
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| JP4742191B2 (ja) * | 2001-06-14 | 2011-08-10 | 独立行政法人産業技術総合研究所 | 糖蛋白質およびその製造方法 |
| PT2266968E (pt) | 2001-07-16 | 2013-02-25 | Genzyme Corp | Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase |
| WO2003045928A1 (en) | 2001-11-26 | 2003-06-05 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| JP5433133B2 (ja) * | 2003-01-22 | 2014-03-05 | デューク・ユニヴァーシティ | リソソームポリペプチドを発現するための改善された構築物 |
| US20100196345A1 (en) | 2003-04-27 | 2010-08-05 | Protalix | Production of high mannose proteins in plant culture |
| BRPI0411843B8 (pt) | 2003-06-24 | 2021-05-25 | Genzyme Corp | ácido nucleico compreendendo um promotor de beta-actina, vetor e método de produzir uma proteína |
| CA2553955C (en) | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| CA2669347A1 (en) * | 2006-11-13 | 2008-05-29 | Zystor Therapeutics, Inc. | Methods for treating pompe disease |
| PL2889043T3 (pl) | 2008-12-16 | 2019-09-30 | Genzyme Corporation | Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko |
| US8466340B2 (en) * | 2009-02-18 | 2013-06-18 | Amicus Therapeutics, Inc. | Mouse model for pompe disease and methods of use thereof |
-
2012
- 2012-04-20 RU RU2013151875/10A patent/RU2013151875A/ru not_active Application Discontinuation
- 2012-04-20 US US14/113,360 patent/US20140186326A1/en not_active Abandoned
- 2012-04-20 EP EP12717025.6A patent/EP2699676A1/en not_active Withdrawn
- 2012-04-20 PH PH1/2013/502149A patent/PH12013502149A1/en unknown
- 2012-04-20 KR KR1020137029936A patent/KR20140037082A/ko not_active Withdrawn
- 2012-04-20 BR BR112013026976A patent/BR112013026976A2/pt not_active IP Right Cessation
- 2012-04-20 JP JP2014506579A patent/JP2014513952A/ja active Pending
- 2012-04-20 AU AU2012245280A patent/AU2012245280A1/en not_active Abandoned
- 2012-04-20 PE PE2013002377A patent/PE20140617A1/es not_active Application Discontinuation
- 2012-04-20 SG SG2013076526A patent/SG194486A1/en unknown
- 2012-04-20 CA CA2833371A patent/CA2833371A1/en not_active Abandoned
- 2012-04-20 SG SG10201605874TA patent/SG10201605874TA/en unknown
- 2012-04-20 MX MX2013012345A patent/MX2013012345A/es not_active Application Discontinuation
- 2012-04-20 CN CN201280030662.2A patent/CN103797115A/zh active Pending
- 2012-04-20 WO PCT/US2012/034479 patent/WO2012145644A1/en not_active Ceased
-
2013
- 2013-10-14 IL IL228871A patent/IL228871A0/en unknown
- 2013-10-16 ZA ZA2013/07696A patent/ZA201307696B/en unknown
- 2013-10-16 NI NI201300110A patent/NI201300110A/es unknown
- 2013-10-17 CL CL2013003010A patent/CL2013003010A1/es unknown
- 2013-10-18 GT GT201300252A patent/GT201300252A/es unknown
- 2013-10-18 TN TNP2013000427A patent/TN2013000427A1/fr unknown
- 2013-10-29 CR CR20130555A patent/CR20130555A/es unknown
- 2013-11-14 MA MA36431A patent/MA35125B1/fr unknown
- 2013-11-20 CO CO13272849A patent/CO6811810A2/es not_active Application Discontinuation
- 2013-11-21 EC ECSP13013036 patent/ECSP13013036A/es unknown
-
2016
- 2016-09-23 JP JP2016185075A patent/JP2017035091A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013151875A (ru) | Модифицированная кислая альфа глюкозидаза с ускоренным процессингом | |
| JP2012095641A5 (enExample) | ||
| GB201018518D0 (en) | Novel endolysin | |
| JP2016509011A5 (enExample) | ||
| JP2018520646A5 (enExample) | ||
| NZ701881A (en) | Vaccines for hsv-2 | |
| JP2012105650A5 (enExample) | ||
| MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
| WO2015024667A8 (en) | Method for increasing expression of rna-encoded proteins | |
| NZ595063A (en) | Polypeptides from neisseria meningitidis | |
| WO2015138357A3 (en) | Compositions useful in treatment of otc deficency | |
| AU2019314383B2 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
| MX336412B (es) | Nuevos analogos de glucagon. | |
| NZ627372A (en) | Clostridium histolyticum enzymes and methods for the use thereof | |
| JP2015508771A5 (enExample) | ||
| WO2014111458A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| EA201790178A1 (ru) | Пептиды, несущие маннозо-6-фосфат, слитые с лизосомальным ферментом | |
| MX364623B (es) | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. | |
| EA201170917A1 (ru) | Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней | |
| MY178445A (en) | Novel antibody binding to tfpi and composition comprising the same | |
| JP2018537089A5 (enExample) | ||
| MY190257A (en) | Optimised subcutaneous therapeutic agents | |
| JP2015514115A5 (enExample) | ||
| JP2018533970A5 (enExample) | ||
| RU2017124487A (ru) | НОВЫЙ ПЕПТИД-ИНГИБИТОР PI3Kγ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯ |